Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Cenyx Biotech

Request full access

Nanozyme therapeutics for acute inflammatory diseases

Seoul, South KoreaFounded 2016Biotech & Life Sciences

About Cenyx Biotech

Cenyx Biotech is a South Korean nanomedicine company founded in 2016 by Professor Seung-Hoon Lee, a neurologist at Seoul National University Hospital (SNUH). The company was established to commercialize a decade's worth of research into nanozymes, which are nanomaterials with enzyme-like characteristics. Professor Lee, who serves as CEO, is a recognized expert in stroke and inorganic nanoparticles, with his research on the effects of cerium oxide nanoparticles on subarachnoid hemorrhage models winning an award from the American Stroke Association in 2018.

The company's core technology is its proprietary InnoSurface® platform, which develops nanozymes designed to scavenge excess free radicals, thereby treating severe acute inflammatory conditions. Its lead candidate, CX213, is a first-in-class, cerium oxide-based nanozyme targeting subarachnoid hemorrhage (SAH), a life-threatening brain bleed with no currently approved emergency treatments. In late 2024, Cenyx received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials for CX213 in the second quarter of 2025. The drug has also received orphan drug designation from the FDA. The company's pipeline also includes CX301, a treatment for acute kidney injury, which is expected to advance toward IND approval in 2025.

Cenyx Biotech's business model is focused on developing its pipeline assets through clinical trials and seeking strategic partnerships for global commercialization. The company operates a research center and is establishing a GMP-compliant manufacturing facility in Seoul. Cenyx has successfully raised capital, including a Series A round of KRW 18.5 billion (approx. $16.5M) in 2021 from investors including SBI Investment Korea, InterValue Partners, and Partners Investment, to fund its clinical trials.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
53.6/100
Industry
Health
Sub-industry
BioTechnology
Sector
Neurology, Critical medical care, Inflammatory Diseases
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Mar 2026 $10M $75M Aju IB Investment · CKD Venture Capital Corporation · SL Investment · Partners Investment ↗
SERIES A✓Equity / VC Apr 2021 $16M $62M Aju IB Investment · Daekyo · CKD Venture Capital Corporation · WONIK Investment Partners —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Cenyx Biotech website traffic

Latest recorded traffic for Cenyx Biotech is 270 monthly website visits, down 86.5% over the last three months.

Latest monthly visits270 3-month web change-86.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Cenyx Biotech in the Seoul ecosystem

Live from Dealroom

The Cenyx Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed4 investors entered at this stage

  • Aju IB Investment
  • CKD Venture Capital Corporation
  • Daekyo Investment
  • WONIK Investment Partners

Series A6 investors entered at this stage

  • Daekyo
  • SL Investment
  • Partners Investment
  • InterValue Partners
  • Scale Up Partners
  • SBI Investment

Other known investors1 additional known investor

  • SBI Investment Korea
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇰🇷 South Korea · Seoul HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Cenyx Biotech on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cenyx Biotech’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.